RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner

Cancer Research

Volumn 74, Issue 22, 2014, Pages 6661-6670

  Hagen, Jussara ^a   Muniz, Viviane P ^a,b   Falls, Kelly C ^a   Reed, Sara M ^a   Taghiyev, Agshin F ^a   Quelle, Frederick W ^a,c   Gourronc, Francoise A ^a   Klingelhutz, Aloysius J ^a,b,c   Major, Heather J ^a   Askeland, Ryan W ^a   Sherman, Scott K ^a   O'dorisio, Thomas M ^a,c   Bellizzi, Andrew M ^a,c   Howe, James R ^a,c   Darbro, Benjamin W ^a,c   Quelle, Dawn E ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN P53; PROTEIN RABL6A; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; UNCLASSIFIED DRUG; ONCOPROTEIN; RAB PROTEIN; RABL6A PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS; ONCOGENE; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RABL6A ONCOGENE; TUMOR CELL; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; HUMANS; MITOSIS; NEUROENDOCRINE TUMORS; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS; RAB GTP-BINDING PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 84918515973     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3742     Document Type: Article

References (50)

1. Vinik AI, Woltering EA, Warner RRP, Caplin M, O'Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008;26:3063-72.
3. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB 2010;12:361-79.
4. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine Tumors of the Pancreas. Oncologist 2009;14:456-67.
5. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9, 821 patients. J Gastrointest Surg 2007;11:1460-7.
6. Falconi M, Bartsch DK, Eriksson B, Kloeppel G, Lopes JM, O'Connor JM, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-34.
7. Sherman SK, Howe JR. Translational research in endocrine surgery. Surg Oncol Clin N Am 2013;22:857-84.
8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-803.
9. Jiao Y, Shi C, Edil BH, deWilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203.
10. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52.
11. Raut CP, Kulke MH. Targeted therapy in advanced well-differentiated neuroendocrine tumors. Oncologist 2011;16:286-95.
12. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
13. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
14. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
15. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003;13:77-83.
16. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73.
17. Arf facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms. PLoS ONE 2010;5:e12454.
18. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ, et al. Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes & Cancer 2010;1:360-8.
19. Tang LH, Contractor T, Clausen R, Klimstra DS, Du Y-CN, Allen PJ, et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased Cdk4/Cdk6. Clin Cancer Res 2012;18:4612-20.
20. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu T-T, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol 2005;18:1632-40.
21. Simon B, Lubomierski N. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis. Ann N Y Acad Sci 2004;1014:284-99.
22. Tompkins V, Hagen J, Zediak VP, Quelle DE. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle 2006;5:641-6.
23. Montalbano J, Jin WX, Sheikh MS, Huang Y. RBEL1is a novelgenethat encodes a nucleocytoplasmic ras superfamily GTP-binding protein and is overexpressed in breast cancer. J Biol Chem 2007;282:37640-9.
24. Montalbano J, Lui K, Sheikh MS, Huang Y. Identification and characterization of RBEL1 subfamily of GTPases in the ras superfamily involved in cell growth regulation. J Biol Chem 2009;284:18129-42.
25. Lui K, An J, Montalbano J, Shi J, Corcoran C, He Q, et al. Negative regulation of p53 by Ras superfamily protein RBEL1A. J Cell Sci 2013;126:2436-45.
26. Li Y-Y, Fu S, Wang X-P, Wang H-Y, Zeng M-S, Shao J-Y. Downregulation of C9orf86 in human breast cancer cells inhibits cell proliferation, invasion and tumor growth and correlates with survival of breast cancer patients. PLoS ONE 2013;8:e71764.
27. Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, et al. RABL6A promotes oxaliplatin resistance in tumor cells and is a new marker of survival for resected pancreatic ductal adenocarcinoma patients. Genes & Cancer 2013;4:273-84.
28. Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, et al. RABL6A, a novel RAB-Like protein, controls centrosome amplification and chromosome instability in primary fibroblasts. PLoS ONE 2013;8:e80228.
29. Townsend CM, Ishizuka J, Thompson JC. Studies of growth regulation in a neuroendocrine cell line. Acta Oncol 1993;32:125-30.
30. Kelley KD, Miller KR, Todd A, Kelley AR, Tuttle R, Berberich SJ. YPEL3, a p53-regulated gene that induces cellular senescence. Cancer Res 2010;70:3566-75.
31. Halbert CL, Demers GW, Galloway DA. The E6-gene and E7-gene of human papillomavirus type-6 have weak immortalizing activity in human epithelial-cells. J Virol 1992;66:2125-34.
32. Darbro BW, Lee KM, Nguyen NK, Domann FE, Klingelhutz AJ. Methylation of the p16 (INK4a) promoter region in telomerase immortalized human keratinocytes co-culturedwith feeder cells. Oncogene 2006;25:7421-33.
33. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
34. Korgaonkar C, Zhao L, Modestou M, Quelle DE. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 2002;22:196-206.
35. di Tommaso A, Hagen J, Tompkins V, Muniz V, Dudakovic A, Kitzis A, et al. Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Exp Cell Res 2009;315:1326-35.
36. Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: A typically cystic carcinoma of low malignant potential. Semin Diagn Pathol 2000;17:66-80.
37. Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, et al. Comparison of clinicopathologic factors in 122 Patients with resected pancreatic and ileal neuroendocrine tumors from a single institution. Ann Surg Oncol 2012;19:966-72.
38. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
39. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes & Development 2000;14:2393-409.
40. Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses. Virology 2012;424:77-98.
41. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G (1)-phase progression. Genes Dev 1999;13:1501-12.
42. Cardozo T, Pagano M. The SCF ubiquitin ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol 2004;5:739-51.
43. Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, et al. A CDK-independent function of mammalian Cks1: targeting of SCF (Skp2) to the CDK inhibitor p27Kip1. Mol Cell 2001;7:639-50.
44. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, et al. The cell-cycle regulatory protein Cks1 is required for SCF (Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001;3:321-4.
45. Franklin DS, Godfrey VI, O'Brien DA, Deng CX, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20:6147-58.
46. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin simian virus-40 oncogenes. Nature 1985;315:115-22.
47. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, etal. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999;22:44-52.
48. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. Embo J 2001;20:6637-47.
49. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
50. Flaherty KT, LoRusso PM, DeMichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012;18:568-76.